RPG Life Sciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The profit appears lower due to the exceptional gain that was recorded in Q4 FY25.

Total operating expenses for Q4 FY26 added up to Rs 144.06 crore, up 22.5% YoY.

Profit before tax in Q4 FY26 stood at Rs 40.20 crore, down by 70.2% from Rs 134.90 crore in Q4 FY25.

For FY26, the company posted net profit and revenue of Rs 115.17 crore (down 37.1% YoY) and Rs 707.52 crore (up 8.3% YoY), respectively.

The company said that in Q4, the Domestic Formulations (DF) business again delivered market-beating growth of 18.2%, compared to the Indian Pharma Market (IPM), which grew by 10.1% in the same period; a 1.8 times growth placing us significantly ahead of the market.

The API division demonstrated strong comeback and registered a growth of 144.3% in Q4 on the back of unit coming back to operations. The growth surge especially stands out considering the fire in our API manufacturing plant in January 2025 and the timely restoration of our facility.

Ashok Nair, managing director, RPG Life Sciences, said: ?Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands.

Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness.?

The board of directors at its meeting held today has recommended a final dividend of Rs 24 per equity share for FY25-26.

RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.

The scrip jumped 10.85% to currently trade at Rs 2242 on the BSE.

Powered by Capital Market - Live News

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 24 per equity Share (i.e. 300%) , subject to the approval of the shareholders.

Net profit of RPG Life Sciences declined 74.52% to Rs 29.90 crore in the quarter ended March 2026 as against Rs 117.35 crore during the previous quarter ended March 2025. Sales rose 23.62% to Rs 176.89 crore in the quarter ended March 2026 as against Rs 143.09 crore during the previous quarter ended March 2025.

For the full year,net profit declined 37.15% to Rs 115.17 crore in the year ended March 2026 as against Rs 183.24 crore during the previous year ended March 2025. Sales rose 8.28% to Rs 707.52 crore in the year ended March 2026 as against Rs 653.43 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Net profit of RPG Life Sciences declined 36.64% to Rs 22.13 crore in the quarter ended December 2025 as against Rs 34.93 crore during the previous quarter ended December 2024. Sales rose 4.24% to Rs 180.03 crore in the quarter ended December 2025 as against Rs 172.71 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News